Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313472776> ?p ?o ?g. }
- W4313472776 endingPage "246" @default.
- W4313472776 startingPage "246" @default.
- W4313472776 abstract "Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of solid tumors. However, although ICIs are better tolerated than conventional chemotherapy, their use is associated with a peculiar toxicity profile, related to the enhancement of the immune response, affecting several organs. Among immune-related adverse events (irAEs), up to 10% involve the endocrine system. Most of them are represented by thyroid disorders (hypothyroidism and hyperthyroidism), mainly correlated to the use of anti-PD-1 and/or anti-PD-L1 agents. Less common endocrine irAEs include hypophysitis, adrenalitis, and metabolic irAEs. A deeper understanding of endocrine toxicities is a critical goal for both oncologists and endocrinologists. A strict collaboration between these specialists is mandatory for early recognition and proper treatment of these patients. In this review we will provide a comprehensive overview of endocrine and metabolic adverse events of ICIs, with particular interest in the pathogenesis, predisposing factors and clinical presentation of these irAEs, and their impact on clinical outcomes of patients. Furthermore, we will summarize the most recent studies and recommendations on the clinical approach to immune-related endocrinopathies with the purpose to optimize the diagnostic algorithm, and to help both oncologists and endocrinologists to improve the therapeutic management of these unique types of irAEs, in a real-life scenario." @default.
- W4313472776 created "2023-01-06" @default.
- W4313472776 creator A5010649029 @default.
- W4313472776 creator A5051002285 @default.
- W4313472776 creator A5055609229 @default.
- W4313472776 creator A5059144188 @default.
- W4313472776 creator A5083590917 @default.
- W4313472776 creator A5086984759 @default.
- W4313472776 creator A5091150576 @default.
- W4313472776 date "2022-12-30" @default.
- W4313472776 modified "2023-09-26" @default.
- W4313472776 title "Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario" @default.
- W4313472776 cites W1556990476 @default.
- W4313472776 cites W1940241680 @default.
- W4313472776 cites W1985905844 @default.
- W4313472776 cites W1999935292 @default.
- W4313472776 cites W2008173042 @default.
- W4313472776 cites W2010671639 @default.
- W4313472776 cites W2022306839 @default.
- W4313472776 cites W2032060513 @default.
- W4313472776 cites W2036195858 @default.
- W4313472776 cites W2043352705 @default.
- W4313472776 cites W2049193229 @default.
- W4313472776 cites W2049553585 @default.
- W4313472776 cites W2055249600 @default.
- W4313472776 cites W2056085563 @default.
- W4313472776 cites W2061824209 @default.
- W4313472776 cites W2066671159 @default.
- W4313472776 cites W2067933166 @default.
- W4313472776 cites W2069643269 @default.
- W4313472776 cites W2071432396 @default.
- W4313472776 cites W2085247907 @default.
- W4313472776 cites W2100228832 @default.
- W4313472776 cites W2109465910 @default.
- W4313472776 cites W2110773108 @default.
- W4313472776 cites W2116169737 @default.
- W4313472776 cites W2127446775 @default.
- W4313472776 cites W2131950300 @default.
- W4313472776 cites W2140460887 @default.
- W4313472776 cites W2144401692 @default.
- W4313472776 cites W2145871366 @default.
- W4313472776 cites W2152897456 @default.
- W4313472776 cites W2160834915 @default.
- W4313472776 cites W2161550811 @default.
- W4313472776 cites W2163184777 @default.
- W4313472776 cites W2163279531 @default.
- W4313472776 cites W2265285917 @default.
- W4313472776 cites W2277326116 @default.
- W4313472776 cites W2291768935 @default.
- W4313472776 cites W2292946576 @default.
- W4313472776 cites W2296110227 @default.
- W4313472776 cites W2305396859 @default.
- W4313472776 cites W2312943839 @default.
- W4313472776 cites W2323028177 @default.
- W4313472776 cites W2338994579 @default.
- W4313472776 cites W2414859413 @default.
- W4313472776 cites W2560367415 @default.
- W4313472776 cites W2572174216 @default.
- W4313472776 cites W2612002454 @default.
- W4313472776 cites W2619530510 @default.
- W4313472776 cites W2760410509 @default.
- W4313472776 cites W2765669958 @default.
- W4313472776 cites W2765702167 @default.
- W4313472776 cites W2768429453 @default.
- W4313472776 cites W2770404972 @default.
- W4313472776 cites W2775520252 @default.
- W4313472776 cites W2776914378 @default.
- W4313472776 cites W2782172222 @default.
- W4313472776 cites W2783137027 @default.
- W4313472776 cites W2803877992 @default.
- W4313472776 cites W2806708871 @default.
- W4313472776 cites W2808870673 @default.
- W4313472776 cites W2808896902 @default.
- W4313472776 cites W2809615201 @default.
- W4313472776 cites W2888599070 @default.
- W4313472776 cites W2891536507 @default.
- W4313472776 cites W2896274372 @default.
- W4313472776 cites W2896438236 @default.
- W4313472776 cites W2900931608 @default.
- W4313472776 cites W2905314444 @default.
- W4313472776 cites W2907564726 @default.
- W4313472776 cites W2912725678 @default.
- W4313472776 cites W2915015601 @default.
- W4313472776 cites W2918950605 @default.
- W4313472776 cites W2920270836 @default.
- W4313472776 cites W2921514982 @default.
- W4313472776 cites W2944384098 @default.
- W4313472776 cites W2945251690 @default.
- W4313472776 cites W2945674342 @default.
- W4313472776 cites W2954626501 @default.
- W4313472776 cites W2962807330 @default.
- W4313472776 cites W2979886379 @default.
- W4313472776 cites W2994862468 @default.
- W4313472776 cites W3005370270 @default.
- W4313472776 cites W3006654174 @default.
- W4313472776 cites W3011058953 @default.
- W4313472776 cites W3015015941 @default.
- W4313472776 cites W3016454554 @default.